Cancer glossary
HER2-low breast cancer: what a low HER2 result means for you
HER2-low means HER2 1+ or 2+ without amplification. What it looks like on a report, how it differs from HER2 0 and ultralow, and when it affects treatment.
Written and medically reviewed by
Dr. Tara EinullaevaMedical oncologist, 9 years in practice. Credentials · reviewed 17 October 2026
In short
HER2-low describes a tumor that has some HER2 protein, but not enough to count as HER2-positive: HER2 1+, or 2+ without gene amplification on ISH. This status matters mainly in metastatic breast cancer.
How it appears in your report
The phrase ‘HER2-low’ may not appear at all. You can recognize it from these combinations:
- ‘HER2: 1+’ — HER2-low;
- ‘HER2: 2+, FISH: no amplification’ — HER2-low;
- ‘HER2: 0, faint incomplete membrane staining in ≤10% of cells’ — this describes HER2-ultralow;
- ‘HER2: 0, no staining’ — HER2-negative in the strict sense.
What it means
| Status | Result |
|---|---|
| HER2-negative | IHC 0, no membrane staining |
| HER2-ultralow | IHC 0, membrane staining in more than 0% but no more than 10% of cells |
| HER2-low | IHC 1+, or IHC 2+ with negative ISH |
| HER2-positive | IHC 3+, or IHC 2+ with positive ISH |
NCI estimates that about 50–60% of all breast cancers are HER2-low. The line between 0 and 1+ is subjective, and pathologists do not always agree on it. Yet it decides eligibility: the DESTINY-Breast04 trial, on which the approval was based, did not include patients with HER2 0.
Does it affect treatment
In early-stage cancer, no: treatment follows the HER2-negative approach. In metastatic cancer, HER2-low and ultralow status opens access to trastuzumab deruxtecan. In the US it was approved in 2022 for HER2-low disease after chemotherapy for metastatic cancer, and in 2025 for HR-positive HER2-low and ultralow cancer after one or more lines of hormone therapy. Whether and when this is an option for you is your treating doctor’s decision.
Questions to ask your doctor
- Is my result 0 or 1+? If 0, is there faint staining (ultralow)?
- Should the slides be reviewed or HER2 retested on fresh tissue?
- When could this drug be considered in my situation?
If a HER2 0 result in metastatic cancer raises questions, you can get a second opinion. More in the article on IHC in breast cancer.
Sources
- Breast Cancer HER2 Status — American Cancer Society, 2026
- Enhertu Approved for HER2-Low Breast Cancer — National Cancer Institute, 2022
- T-DXd Approved by the FDA for Pretreated Patients With HER2-Low or -Ultralow Metastatic Breast Cancer — The ASCO Post, 2025
- Recommendations for HER2 Testing in Breast Cancer: 2023 Update — College of American Pathologists / ASCO, 2023
FAQ
Related terms
This is reference information and not a substitute for medical advice. Your doctor interprets each value in the context of your whole situation.
